Cargando…
The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery
PURPOSE: This article aimed to study the prognostic value of preoperative plasma fibrinogen and CA19-9 in non-distant metastatic breast cancer (BC). PATIENTS AND METHODS: A total of 343 non-distant metastatic BC patients were included in this study. The optimal cut-off values of plasma fibrinogen an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520160/ https://www.ncbi.nlm.nih.gov/pubmed/33061583 http://dx.doi.org/10.2147/CMAR.S270385 |
_version_ | 1783587724533432320 |
---|---|
author | Hu, Wenjing Zheng, Chen Quan, Ruida Dai, Xuanxuan Zhang, Xiaohua |
author_facet | Hu, Wenjing Zheng, Chen Quan, Ruida Dai, Xuanxuan Zhang, Xiaohua |
author_sort | Hu, Wenjing |
collection | PubMed |
description | PURPOSE: This article aimed to study the prognostic value of preoperative plasma fibrinogen and CA19-9 in non-distant metastatic breast cancer (BC). PATIENTS AND METHODS: A total of 343 non-distant metastatic BC patients were included in this study. The optimal cut-off values of plasma fibrinogen and CA19-9 were obtained by receiver operating characteristic (ROC) curve analysis. Univariate and multivariate Cox regression analyses were used to evaluate prognostic factors for overall survival (OS). Survival data were assessed using Kaplan–Meier survival analysis with the Log-rank test. Based on the cut-off values, we classified the fibrinogen-CA19-9 score as follows: 2 (both hyperfibrinogenemia and high CA19-9), 1 (either hyperfibrinogenemia or high CA19-9), and 0 (neither hypefibrinogenemia nor high CA19-9). RESULTS: Our follow-up time totaled 10 years, the median follow-up time was 77 months (range=2–119 months), and 82 (23.9%) of 343 patients died during the follow-up period. The optimal cut-off values of plasma fibrinogen and CA19-9 were 2.805 g/L and 11.85 U/mL, respectively. The multivariate Cox analysis results suggested that there was a significant association between worse OS and elevated preoperative plasma fibrinogen and CA19-9 levels (HR=2.016, 95% CI=1.216–3.342, P=0.007; and HR=2.042, 95% CI=1.282–3.253, P=0.003). The area under the ROC curve (AUC) increased from 0.589 (for plasma fibrinogen) and 0.594 (for CA19-9) to 0.640 when these two parameters were combined. When we added this combined factor to the multivariate analysis, it was an independent prognostic factor for BC (P<0.001). According to the above results, we chose four prognostic factors to construct our nomogram. The AUC was 0.724, which indicates that the nomogram performs well. CONCLUSION: The combination of plasma fibrinogen and CA19-9 could be used as a valid independent prognostic factor for non-distant metastatic BC compared with either parameter alone and could easily be applied in clinical practice. |
format | Online Article Text |
id | pubmed-7520160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75201602020-10-14 The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery Hu, Wenjing Zheng, Chen Quan, Ruida Dai, Xuanxuan Zhang, Xiaohua Cancer Manag Res Original Research PURPOSE: This article aimed to study the prognostic value of preoperative plasma fibrinogen and CA19-9 in non-distant metastatic breast cancer (BC). PATIENTS AND METHODS: A total of 343 non-distant metastatic BC patients were included in this study. The optimal cut-off values of plasma fibrinogen and CA19-9 were obtained by receiver operating characteristic (ROC) curve analysis. Univariate and multivariate Cox regression analyses were used to evaluate prognostic factors for overall survival (OS). Survival data were assessed using Kaplan–Meier survival analysis with the Log-rank test. Based on the cut-off values, we classified the fibrinogen-CA19-9 score as follows: 2 (both hyperfibrinogenemia and high CA19-9), 1 (either hyperfibrinogenemia or high CA19-9), and 0 (neither hypefibrinogenemia nor high CA19-9). RESULTS: Our follow-up time totaled 10 years, the median follow-up time was 77 months (range=2–119 months), and 82 (23.9%) of 343 patients died during the follow-up period. The optimal cut-off values of plasma fibrinogen and CA19-9 were 2.805 g/L and 11.85 U/mL, respectively. The multivariate Cox analysis results suggested that there was a significant association between worse OS and elevated preoperative plasma fibrinogen and CA19-9 levels (HR=2.016, 95% CI=1.216–3.342, P=0.007; and HR=2.042, 95% CI=1.282–3.253, P=0.003). The area under the ROC curve (AUC) increased from 0.589 (for plasma fibrinogen) and 0.594 (for CA19-9) to 0.640 when these two parameters were combined. When we added this combined factor to the multivariate analysis, it was an independent prognostic factor for BC (P<0.001). According to the above results, we chose four prognostic factors to construct our nomogram. The AUC was 0.724, which indicates that the nomogram performs well. CONCLUSION: The combination of plasma fibrinogen and CA19-9 could be used as a valid independent prognostic factor for non-distant metastatic BC compared with either parameter alone and could easily be applied in clinical practice. Dove 2020-09-23 /pmc/articles/PMC7520160/ /pubmed/33061583 http://dx.doi.org/10.2147/CMAR.S270385 Text en © 2020 Hu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hu, Wenjing Zheng, Chen Quan, Ruida Dai, Xuanxuan Zhang, Xiaohua The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery |
title | The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery |
title_full | The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery |
title_fullStr | The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery |
title_full_unstemmed | The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery |
title_short | The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery |
title_sort | prognostic value of combination of plasma fibrinogen and ca19-9 in non-distant metastatic breast cancer patients undergoing surgery |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520160/ https://www.ncbi.nlm.nih.gov/pubmed/33061583 http://dx.doi.org/10.2147/CMAR.S270385 |
work_keys_str_mv | AT huwenjing theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT zhengchen theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT quanruida theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT daixuanxuan theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT zhangxiaohua theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT huwenjing prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT zhengchen prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT quanruida prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT daixuanxuan prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery AT zhangxiaohua prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery |